Clinical Chemistry AACC Online Job Center
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 43: 2225-2229, 1997;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via ISI Web of Science (1)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Relman, A. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Relman, A. S.
Related Collections
Right arrow Laboratory Management
(Clinical Chemistry. 1997;43:2225-2229.)
© 1997 American Association for Clinical Chemistry, Inc.

The AACC Lectureship Award Address

The market for health care: where is the patient?

Arnold S. Relman

Brigham & Women's Hospital, 181 Longwood Ave., 5th Fl., Boston, MA 02115-5804. Fax 617/525-2186; e-mail arelman@rics.bwh.harvard.edu.

In 1980 I wrote an article in the New England Journal of Medicine (1) in which I said that the most important new development in the US health care system was the recent, relatively unheralded rise of a huge new industry that supplied medical services for profit. Without attracting much public attention, investor-owned businesses had begun to take over large parts of a health system which until then had been largely community-based and not-for-profit. At that time the major components of this new industry were proprietary hospitals and nursing homes, diagnostic laboratories, home-care and emergency room services, and hemodialysis centers. In total, these businesses had already captured almost a quarter of all the revenues spent for personal health care and I predicted their rapid growth would soon make them not only a dominating force in our health care delivery system, but also a major influence on public policy.

There was an obvious analogy between this burgeoning, highly profitable new industry and the "military-industrial complex" that Dwight Eisenhower had warned about in his farewell address as President in 1961, so I called it the "new medical-industrial complex". As the significance of the commercial transformation of this country's health care system became increasingly apparent, this subject began to attract widening interest in the popular media and in the professional literature.

Paul Starr's 1982 landmark study of the social and economic development of medicine in America (2) was the first major scholarly work to take up this theme and put it in broad historical context. After devoting most of his book to the rise of the medical profession and its struggle for professional autonomy, Starr wrote a final chapter, entitled "The Coming of the Corporation", which described the new corporate transformation of the US health care system and its . . . [Full Text of this Article]


References






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1997 by the American Association for Clinical Chemistry.